The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| INDP | -92.51% | -99.46% | -64.82% | -99% |
| S&P | +12.94% | +86.25% | +13.25% | +55% |
Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company. It engages in the development of a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. The firm created patented treatment methods and associated patented compositions for attenuation and killing of non-pathogenic, Gram-negative bacteria. The company was founded by Michael James Newman on February 24, 2021 and is headquartered in New York, NY.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 0.0% |
| Market Cap | $3.18M | -74.9% |
| Market Cap / Employee | $0.45M | 0.0% |
| Employees | 7 | 0.0% |
| Net Income | -$2.98M | 3.1% |
| EBITDA | -$2.65M | 15.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $5.83M | -21.1% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | -100.0% |
| Short Term Debt | $0.01M | -91.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -223.71% | -109.3% |
| Return On Invested Capital | 184.10% | 1.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$3.05M | -20.7% |
| Operating Free Cash Flow | -$3.05M | -20.7% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.56 | 3.15 | 60.31 | -1.04 | -149.26% |
| Price to Tangible Book Value | 40.05 | 46.89 | 60.31 | -1.04 | -102.15% |
| Enterprise Value to EBITDA | -0.87 | -0.86 | -1.44 | 1.12 | -177.57% |
| Return on Equity | -187.5% | -259.0% | -755.0% | -318.0% | 127.77% |
| Total Debt | $0.08M | $0.06M | $6.54M | $0.01M | -91.96% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
